Clinical Trial Update: Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of concurrent chemoradiotherapy with surufatinib and tislelizumab for locally advanced non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Surufatinib, Tislelizumab | Phase 2 | Status: RECRUITING